To receive the Femtech World newsletter, sign up here.
News
Fertility benefits platform Apryl partners with period tracker Clue
The partnership is hoped to help women better monitor their fertility and understand their health
The Berlin-based fertility benefits provider Apryl has teamed up with the period tracking app Clue to boost its offerings.
Apryl is a fertility benefits platform that helps employers attract and retain top talent while tackling diversity and inclusion.
The company seeks to help employers support their employees with fertility and family planning benefits, including consultation, access to clinics, treatments and adoption.
Through its partnership with Clue, Apryl aims to “equip” individuals with the tools they need for monitoring their fertility.
“Our vision at Apryl is to revolutionise the workplace by making fertility and family planning benefits universally accessible and inclusive,” said Jenny Saft, co-founder and CEO of Apryl.
“We believe that supporting employees in their personal life goals leads to enhanced job satisfaction and retention. This partnership with Clue enables us to provide a more rounded suite of resources that supports this vision.
“Employers can now also offer these enriched benefits as part of their reimbursable budget.”
The collaboration will give Apryl members an exclusive discount on the annual Clue Plus subscription, which includes premium features that could help women better understand their reproductive health and boost their chances of conception.
Saft said: “I’m particularly proud of this partnership because it significantly expands the services available to Apryl’s members, it is accessible globally, and it creates a win-win-win situation for everyone involved: our company, Clue, and most importantly, the members who utilise our platform.”
The integration of Clue’s services into Apryl’s platform is just the beginning, the CEO added.
“As we expand into new regions, we will keep enhancing our platform with services and partnerships that support the varying needs of our users.
“We believe this partnership is a milestone in our journey to redefine fertility and family planning benefits. By joining forces with Clue, we are one step closer to building a more inclusive and supportive workplace environment around the world.”
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







2 Comments